Related Experiment Videos
c-Met: structure, functions and potential for therapeutic inhibition
Patrick C Ma1, Gautam Maulik, James Christensen
1Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
Cancer Metastasis Reviews
|July 30, 2003
Summary
Dysregulated c-Met signaling, often due to mutations, drives cancer invasion and metastasis. Targeting c-Met offers a promising therapeutic strategy for various malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Receptor tyrosine kinases (RTKs) are crucial in cancer therapy.
- c-Met, an RTK, is frequently overexpressed or mutated in malignancies.
- c-Met dysregulation promotes tumor invasion and metastasis.
Purpose of the Study:
- To review the role of c-Met dysregulation in tumor progression and metastasis.
- To emphasize the impact of c-Met mutations on cancer.
- To summarize c-Met signal transduction pathways and their role in cytoskeletal functions.
Main Methods:
- Literature review focusing on c-Met signaling pathways and mutations.
- Analysis of c-Met's role in tumor invasion and metastasis.
- Inclusion of laboratory data on c-Met stimulation in lung cancer cells.
Main Results:
- c-Met activating mutations are prevalent in solid tumors, driving invasion and metastasis.
- Hepatocyte growth factor (HGF/SF) stimulation of c-Met triggers scattering, angiogenesis, proliferation, and motility.
- c-Met stimulation leads to phosphorylation of focal adhesion proteins like paxillin, p125FAK, and PYK2 in lung cancer cells.
Conclusions:
- Dysregulated c-Met, through mutations or overexpression, is a significant driver of cancer progression.
- c-Met signaling pathways are critical for cytoskeletal regulation and cell motility.
- Targeting mutated or overexpressed c-Met presents a key therapeutic opportunity in cancer treatment.